- Home
- DMAC vs VBNK Comparison
DMAC vs VBNK Comparison
Compare DMAC & VBNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- VBNK
- Stock Information
- Founded
- DMAC 2000
- VBNK 1980
- Country
- DMAC United States
- VBNK Canada
- Employees
- DMAC N/A
- VBNK N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- VBNK Commercial Banks
- Sector
- DMAC Health Care
- VBNK Finance
- Exchange
- DMAC Nasdaq
- VBNK Nasdaq
- Market Cap
- DMAC 321.5M
- VBNK 374.8M
- IPO Year
- DMAC N/A
- VBNK 2021
- Fundamental
- Price
- DMAC $5.95
- VBNK $11.95
- Analyst Decision
- DMAC Strong Buy
- VBNK Buy
- Analyst Count
- DMAC 4
- VBNK 2
- Target Price
- DMAC $15.50
- VBNK $15.00
- AVG Volume (30 Days)
- DMAC 315.3K
- VBNK 43.0K
- Earning Date
- DMAC 11-12-2025
- VBNK 12-08-2025
- Dividend Yield
- DMAC N/A
- VBNK 0.61%
- EPS Growth
- DMAC N/A
- VBNK N/A
- EPS
- DMAC N/A
- VBNK 0.69
- Revenue
- DMAC N/A
- VBNK $82,297,771.00
- Revenue This Year
- DMAC N/A
- VBNK $12.20
- Revenue Next Year
- DMAC N/A
- VBNK $30.76
- P/E Ratio
- DMAC N/A
- VBNK $18.47
- Revenue Growth
- DMAC N/A
- VBNK 0.07
- 52 Week Low
- DMAC $3.19
- VBNK $8.51
- 52 Week High
- DMAC $7.49
- VBNK $18.38
- Technical
- Relative Strength Index (RSI)
- DMAC 42.03
- VBNK 46.74
- Support Level
- DMAC $5.26
- VBNK $11.58
- Resistance Level
- DMAC $6.47
- VBNK $11.74
- Average True Range (ATR)
- DMAC 0.41
- VBNK 0.30
- MACD
- DMAC -0.10
- VBNK -0.01
- Stochastic Oscillator
- DMAC 36.50
- VBNK 28.91
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About VBNK VersaBank
VersaBank is a Canadian Schedule I chartered bank with a difference. It has 3 operating segments: Digital Banking Canada, Digital Banking USA and DRTC. It's, cloud-based, business-to-business deposit and lending model provides valued-added solutions to Canadian financial intermediary partners, enabling them to focus on growing their own businesses faster and more profitably. It obtains all of its deposits and provides the majority of its loans and leases electronically, with deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, Company established a wholly owned, subsidiary. Geographically located in Canada and USA.